CSL Ltd. — Capital/Financing Update 2010

Jan 27, 2010

==> picture [138 x 58] intentionally omitted <==

==> picture [230 x 58] intentionally omitted <==

==> picture [86 x 58] intentionally omitted <==

ASX & Media Release

Patrys to work w ith CSL to explore antibody drugs

Melbourne, Australia; 28 Jan u ary, 2010: Patrys Limited (ASX: PAB), a biophar m aceutical company focused on the development of safer and more effective treatments for canc e r and other major diseases, announced today th a t it had entered into an agreement with CSL Limit e d (ASX:CSL) that is focused on several Patrys anti b ody therapeutic candidates.

Under the agreement, Patrys h as granted CSL an exclusive right to research an d develop products based on two early stage antibodies from Patrys’ pipeline. CSL will pay Patrys an u ndisclosed upfront amount and undertake the res e arch and development of antibodies at its own cost.

In addition to the upfront pay m ents, Patrys will also receive a number of milesto n e payments in the first 30 months of the agreem e nt, and beyond, if development goals are met. Patrys is also entitled to royalties on sales once resul t ing products reach the market.

As part of the agreement, CSL h as the right to select up to two additional early st a ge antibodies from Patrys’ pipeline for research a n d development at CSL’s cost. The exercise of thi s right, which has a defined expiration period, wo u ld also trigger upfront payments, contingent dev e lopment milestone payments and royalties.

Specific financial and other co m mercial terms of the agreement are confidential.

The agreement does not cover Patrys’ most advanced lead products PAT-SM6, PAT-LM1 and PATSC1.

Patrys CEO Dan Devine said, “ T his collaboration has many elements necessary f o r success. CSL is a global biotech company with t h e necessary experience to develop and commercialise antibodies.”

“In addition, CSL has committed to invest the time and resources needed t o properly explore, advance and develop these e a rly stage product opportunities. This factor has the added benefit of allowing Patrys to focus its ef f orts and resources on the clinical development o f our more mature product candidates.”

“Finally, as CSL is local, our teams can work seamlessly together to ensure that the projects move forward as effectively as possi b le.”

Dr Andrew Nash from CSL ad d ed, “Patrys has developed a novel approach to t h e identification of potential therapeutic antibodi e s and targets for the treatment of cancer. We look forward to working with them to identify candidat e s suitable for further development. ”

-Ends-

==> picture [138 x 58] intentionally omitted <==

==> picture [230 x 58] intentionally omitted <==

==> picture [86 x 58] intentionally omitted <==

For further information, pleas e contact:

Patrys Limited: Patrys Media: Daniel Devine Kyahn Williamson Chief Executive Officer Buchan Consulting P: +61 3 9670 3273 P: +61 3 9866 4722 or 040 101 882 8 info@patrys.com kwilliamson@bcg.com.au

About Patrys Limited:

Based in Melbourne, Australia, Pa t rys (ASX: PAB) is focused on the development of thera p ies for cancer and other major diseases. Patrys has a d e ep pipeline of anti-cancer natural human antibodies t h at enable both internal development and partnering oppo r tunities. More information can be found at www.patrys. c om.